Tin tức & Cập nhật

More and more patients in the US are being initiated on immunotherapy within 1 month of death, reflecting the rise in use of immunotherapy overall, according to a study.

In the primary analysis of the expanded-access ZUMA-18 trial, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) demonstrated a high level of efficacy in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Proton pump inhibitor (PPI) co-therapy appears to lower the risk of hospitalization for upper gastrointestinal bleeding (UGIB) in atrial fibrillation (AF) patients receiving direct oral anticoagulant (DOAC) treatment, according to a study from Korea.

Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.